CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $906,517, lower than 95% of all stocks globally
- PositionGross margin is -18.9%, lower than 95% of its Biotechnology peers (median 67.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
75.70BTWD2.37B · vs all stocks (USD)
Revenue (TTM)
28.93MTWD906.52K · vs all stocks (USD)
Profit Margin
-13.97%vs Biotechnology peers
52-Week Change
195.39%vs all stocks
Market Capitalization
75.70BTWD2.37B · vs all stocks (USD)
Enterprise Value
71.65BTWD2.25B · vs all stocks (USD)
Price to Book (MRQ)
29.74xvs Biotechnology peers
Enterprise to Revenue
2.48Kxvs Biotechnology peers
Enterprise to EBITDA
-154.95xvs Biotechnology peers
Gross Margin
-18.92%vs Biotechnology peers
Profit Margin
-13.97%vs Biotechnology peers
Operating Margin
-1221.13%vs Biotechnology peers
Return on Assets (TTM)
-12.91%vs Biotechnology peers
Return on Equity (TTM)
-24.19%vs Biotechnology peers
Revenue (TTM)
28.93MTWD906.52K · vs all stocks (USD)
Revenue per Share (TTM)
0.4660TWDUpdated Aug 21, 2026Quarterly Revenue Growth
52.50%vs Biotechnology peers
Gross Profit (TTM)
-10.42MTWD-326.47K · vs all stocks (USD)
EBITDA (TTM)
-462.41MTWD-14.49M · vs all stocks (USD)
Net Income (TTM)
-435.85MTWD-13.66M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-46.68%vs Biotechnology peers
Operating Cash Flow (TTM)
-400.03MTWD-12.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-327.27MTWD-10.26M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00TWDUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
272.06MTWDFY2025 · Dec 31, 2025Revenue
31.42MTWDFY2025 · Dec 31, 2025Cost of Goods Sold
35.81MTWDFY2025 · Dec 31, 2025Gross Profit
-4.39MTWDFY2025 · Dec 31, 2025Operating Income
-467.35MTWD-14.65M · vs all stocks (USD)
Pre-tax Income
-452.67MTWDFY2025 · Dec 31, 2025Income Tax Expense
0.00TWDFY2025 · Dec 31, 2025Net Income
-452.67MTWDFY2025 · Dec 31, 2025EBIT
-450.63MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-403.51MTWDFY2025 · Dec 31, 2025Research & Development
252.66MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
210.29MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
11.91MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.04MTWDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-452.67MTWDFY2025 · Dec 31, 2025Minority Interests (P&L)
28.73MTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
-385.53MTWDFY2025 · Dec 31, 2025Free Cash Flow
-611.95MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
306.70MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-452.67MTWDFY2025 · Dec 31, 2025Stock-based Compensation
75.12MTWDFY2025 · Dec 31, 2025Other Non-cash Items
-9.86MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.32MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
3.20MTWDFY2025 · Dec 31, 2025Capital Expenditures
-226.41MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.19MTWDFY2025 · Dec 31, 2025Purchase of Investments
-1.20BTWDFY2025 · Dec 31, 2025Sale of Investments
913.94MTWDFY2025 · Dec 31, 2025Other Investing Activity
20.78MTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
-495.95MTWDFY2025 · Dec 31, 2025Long-term Debt Payments
-100.00MTWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-100.00MTWDFY2025 · Dec 31, 2025Other Financing Charges
216.00MTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
585.32MTWDFY2025 · Dec 31, 2025Shares Outstanding
64.88MSharesUpdated Aug 21, 2026Float Shares
35.33MSharesUpdated Aug 21, 2026% Held by Insiders
0.00%vs all stocks
% Held by Institutions
0.47%vs all stocks
Total Cash (MRQ)
2.27BTWD71.10M · vs all stocks (USD)
Total Cash per Share (MRQ)
34.71TWDUpdated Aug 21, 2026Total Debt (MRQ)
130.13MTWD4.08M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0461xvs Biotechnology peers
Current Ratio (MRQ)
10.07xvs Biotechnology peers
Book Value per Share (MRQ)
39.35TWDUpdated Aug 21, 2026Total Assets
2.11BTWD66.19M · vs all stocks (USD)
Total Current Assets
1.33BTWDFY2025 · Dec 31, 2025Total Liabilities
418.27MTWDFY2025 · Dec 31, 2025Total Non-current Assets
780.80MTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
109.30MTWDFY2025 · Dec 31, 2025Total Current Liabilities
308.97MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
306.70MTWDFY2025 · Dec 31, 2025Other Short-term Investments
1.00BTWDFY2025 · Dec 31, 2025Accounts Receivable
5.07MTWDFY2025 · Dec 31, 2025Inventory
6.62MTWDFY2025 · Dec 31, 2025Accounts Payable
5.70MTWDFY2025 · Dec 31, 2025Short-term Debt
128.12MTWDFY2025 · Dec 31, 2025Other Current Liabilities
4.89MTWDFY2025 · Dec 31, 2025Long-term Debt
109.28MTWDFY2025 · Dec 31, 2025Other Non-current Liabilities
18.00KTWDFY2025 · Dec 31, 2025Common Stock (Book)
1.14BTWDFY2025 · Dec 31, 2025Retained Earnings
-1.63BTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.69BTWD53.08M · vs all stocks (USD)
Treasury Stock
800.00KTWDFY2025 · Dec 31, 202552-Week Low
308.50TWDUpdated Aug 21, 202652-Week High
1.19KTWDUpdated Aug 21, 202652-Week Change
195.39%vs all stocks
50-Day MA
928.00TWDUpdated Aug 21, 2026200-Day MA
645.80TWDUpdated Aug 21, 2026Avg 10-Day Volume
207.20KSharesUpdated Aug 21, 2026Avg 30-Day Volume
255.13KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-7.20TWDUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -18.9%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: -0.19Industry median: 0.67Industry P5: 0.14Peers compared: 261
Price-to-book is 29.74×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 29.74Industry median: 2.97Industry P95: 23.50Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.63
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $906,517, lower than 95% of all stocks globallySignificant
Revenue (USD): 906,516.736Global P5: 30,274,777.221
Market cap is $2.37B, above the global median of $1.15BNotable
Market cap (USD): 2,372,171,971.612Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
BrightGene Bio-Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prestige Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vericel Corporation
Tier 1ProductionApproval-Gated PipelineRule
BioCryst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mineralys Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nurix Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Biohaven Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pharvaris N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
DigitalBridge Group Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Erasca, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Relay Therapeutics Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity